These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 16980747)
1. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. Sharvadze L; Tsertsvadze T; Gochitashvili N; Kakabadze T; Dolmazashvili E Georgian Med News; 2006 Aug; (137):62-5. PubMed ID: 16980747 [TBL] [Abstract][Full Text] [Related]
2. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354 [TBL] [Abstract][Full Text] [Related]
4. Anemia in the treatment of hepatitis C virus infection. Sulkowski MS Clin Infect Dis; 2003; 37 Suppl 4():S315-22. PubMed ID: 14582000 [TBL] [Abstract][Full Text] [Related]
5. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. Sharvadze L; Gochitashvili N; Tophuria A; Bolokadze N; Tsertsvadze T Georgian Med News; 2007 Jun; (147):52-5. PubMed ID: 17660602 [TBL] [Abstract][Full Text] [Related]
6. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326 [TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715 [TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Bräu N J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320 [TBL] [Abstract][Full Text] [Related]
10. Role of epoetin alfa in maintaining ribavirin dose. Afdhal NH Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101 [TBL] [Abstract][Full Text] [Related]
11. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy. Voravud N; Sriuranpong V; Suwanrusme H J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933 [TBL] [Abstract][Full Text] [Related]
13. The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin. Devine EB; Cross JT; Kowdley KV; Sullivan SD Curr Med Res Opin; 2007 Jun; 23(6):1463-72. PubMed ID: 17559739 [TBL] [Abstract][Full Text] [Related]
14. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U; Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286 [TBL] [Abstract][Full Text] [Related]
16. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. De Franceschi L; Fattovich G; Turrini F; Ayi K; Brugnara C; Manzato F; Noventa F; Stanzial AM; Solero P; Corrocher R Hepatology; 2000 Apr; 31(4):997-1004. PubMed ID: 10733558 [TBL] [Abstract][Full Text] [Related]
17. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368 [TBL] [Abstract][Full Text] [Related]
18. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914 [TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778 [TBL] [Abstract][Full Text] [Related]